5/10/2025

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ETCompany ParticipantsRick Winningham - Chief Executive...

Source: SeekingAlpha

5/9/2025

TBPH reports weaker-than-expected first-quarter 2025 results. Collaboration revenues from Viatris rise year over year.

Source: Yahoo

5/9/2025

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massachusetts.

Source: Yahoo

5/9/2025

Theravance Biopharma, Inc. announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic...

Source: Finnhub

5/9/2025

Theravance Biopharma Inc (TBPH) reports a robust 6% increase in net sales and significant hospital channel momentum, while navigating increased expenses and litigation issues.

Source: Yahoo

5/8/2025

Theravance Bio (TBPH) delivered earnings and revenue surprises of -54.55% and 4.20%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Source: Yahoo

5/8/2025

Theravance Biopharma First Quarter 2025 Financial Results and Business Update May 8, 2025 THERAVANCE BIOPHARMA®,...

Source: Finnhub

5/8/2025

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2025.

Source: Yahoo

4/28/2025

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) will be presented at the International MSA Congress, taking place May 9-11, 2025, in Boston, Massachusetts. These analyses support the Company's understanding of ampreloxetine's highly selective mechanism of action and potential to address symptoms of neurogenic orthostatic hypotension (nOH) in patients with multip

Source: Yahoo

4/24/2025

Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2025 financial results and provide a business update after market close on Thursday, May 8, 2025. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EDT (2:00 pm PDT/10:00 pm IST) that day.

Source: Yahoo

4/7/2025

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses from its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH). Both analyses were presented as platform presentations at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California. Findings support ampreloxetine's h

Source: Yahoo

3/31/2025

Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on Wednesday, April 9 at 11:30 am PDT (2:30 pm EDT/6:30 PM GMT).

Source: Yahoo

3/28/2025

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Source: Yahoo

3/27/2025

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine (Studies 169 and 170) supporting its selective and differentiated pharmacodynamic profile will be presented at the 77th Annual Meeting of the American Academy of Neurology (AAN) Meeting, taking place April 5-9, 2025, in San Diego, California. Results from these initial studies led to the initiation of a Phase 3 confirmatory study (CYPRES

Source: Yahoo

3/10/2025

Despite recent progress, significant risks remain, leading me to stay on the sidelines regarding investment in Theravance. Explore more details here.

Source: SeekingAlpha

2/28/2025

Theravance Biopharma ( NASDAQ:TBPH ) Full Year 2024 Results Key Financial Results Revenue: US$64.4m (up 12% from FY...

Source: Yahoo

2/27/2025

TBPH's fourth-quarter earnings match estimates while sales beat the same marginally. Increased collaboration revenues from Viatris drive revenues higher.

Source: Yahoo

2/27/2025

Theravance Biopharma Inc (TBPH) reports robust growth in Upell sales and secures a significant milestone payment, while navigating regulatory and market challenges.

Source: Yahoo

2/26/2025

Theravance Biopharma Fourth Quarter & Full Year 2024 Financial Results and Business Update February 26, 2025 THERAVANCE BIOPHARMA®,...

Source: Finnhub

2/26/2025

Theravance Bio (TBPH) delivered earnings and revenue surprises of 0% and 3.50%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Source: Yahoo